Sign in
Click here - to use the wp menu builder
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Monday, December 23, 2024
Sign in / Join
Facebook
Instagram
Twitter
Vimeo
Youtube
Pharma Deals
Update
Oncology
Search
LATEST ARTICLES
Merger & Acquisition
Merck Acquired Harpoon Therapeutics, Inc.
pharmaquotient.com
-
11 March 2024
0
Appointments
Robert A. Michael Has Been Named Chief Executive Officer by AbbVie
pharmaquotient.com
-
20 February 2024
0
Merger & Acquisition
Bristol Mayers Squibb Agrees to Acquire Mirati Therapeutics to Diversify its Oncology Portfolio for up to $5.8 B
pharmaquotient.com
-
8 October 2023
0
Clinical update
Novartis Announced Positive Phase III Results of Iptacopan in Proteinuria ReductionÂ
pharmaquotient.com
-
2 October 2023
0
Merger & Acquisition
Novartis Divests front of eye Ophthalmic Assets to Bausch+Lomb
pharmaquotient.com
-
29 September 2023
0
generic
Sandoz Received EU Approval of Tyruko® (natalizumab) for multiple sclerosis in Europe
pharmaquotient.com
-
26 September 2023
0
Regulatory update
Abbvie Announces EU Approval of Tepkinly (epcoritamab) for Adults with R/R Diffuse Large B-cell Lymphoma
pharmaquotient.com
-
25 September 2023
0
Clinical update
Allergan Aesthetics Announces Positive Result from Phase 3 Study of OnabotulinumtoxinA (Botox cosmetics)
pharmaquotient.com
-
18 September 2023
0
Clinical update
AbbVie’s SKYRIZI® (risankizumab) outdo Stelara® (ustekinumab) in Head-to-Head Study in Crohn’s Disease
pharmaquotient.com
-
12 September 2023
0
Collaboration agreement
Otsuka and ShapeTXÂ collaborates to develop novel AAV gene therapies for ocular diseases for up to $1.5B
pharmaquotient.com
-
8 September 2023
0
1
2
3
4
...
7
Page 3 of 7
Most Popular
Neuralink’s Blindsight: A Breakthrough in Vision Restoration
20 September 2024
Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025
17 September 2024
Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.
9 September 2024
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
7 September 2024
Load more
Recent Comments
Rahul
on
US FDA Approves Zurzuvae For Postpartum Depression
Rahul
on
JNJ Expands Cancer Portfolio with TALVEY Approval
Ashish
on
Flagship Pioneering Partners with Pfizer to Bolster Development of Innovative Medicine for $50M upfront
Recent Comments